Tozorakimab - Placebo, -, Tozorakimab clinical trials

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.